Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis

Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis

Abstract In preclinical studies rapamycin was found to target neuroinflammation, by expanding regulatory T cells, and affecting autophagy, two pillars of amyotrophic lateral sclerosis (ALS) pathogenesis. Herein we report a multicenter, randomized, double-blind trial, in 63 ALS patients who were rand...

Full description

Bibliographic Details
Main Authors: Jessica Mandrioli, Roberto D’Amico, Elisabetta Zucchi, Sara De Biasi, Federico Banchelli, Ilaria Martinelli, Cecilia Simonini, Domenico Lo Tartaro, Roberto Vicini, Nicola Fini, Giulia Gianferrari, Marcello Pinti, Christian Lunetta, Francesca Gerardi, Claudia Tarlarini, Letizia Mazzini, Fabiola De Marchi, Ada Scognamiglio, Gianni Sorarù, Andrea Fortuna, Giuseppe Lauria, Eleonora Dalla Bella, Claudia Caponnetto, Giuseppe Meo, Adriano Chio, Andrea Calvo, Andrea Cossarizza
Format: Article
Language:English
Published: Nature Portfolio 2023-08-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-40734-8

Internet

https://doi.org/10.1038/s41467-023-40734-8

Similar Items